Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer
Standard
Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer. / Schmid, Marianne; Hanske, Julian; Ravi, Praful; Krishna, Nandita; Reznor, Gally; Meyer, Christian P; Fisch, Margit; Noldus, Joachim; Nguyen, Paul L; Trinh, Quoc-Dien.
in: INT J UROL, Jahrgang 23, Nr. 4, 01.04.2016, S. 305-11.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer
AU - Schmid, Marianne
AU - Hanske, Julian
AU - Ravi, Praful
AU - Krishna, Nandita
AU - Reznor, Gally
AU - Meyer, Christian P
AU - Fisch, Margit
AU - Noldus, Joachim
AU - Nguyen, Paul L
AU - Trinh, Quoc-Dien
N1 - © 2016 The Japanese Urological Association.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - OBJECTIVES: To investigate the dose-dependent effect of androgen deprivation therapy on community-acquired respiratory infections in patients with localized prostate cancer.METHODS: We identified 52 905 men diagnosed with localized prostate cancer within the Surveillance, Epidemiology and End Results-Medicare database between 1991 and 2006. We compared those who did not receive androgen deprivation therapy with those who received androgen deprivation therapy within 2 years of diagnosis, calculated as monthly equivalent doses (<7, 7-11, >11 doses), or orchiectomy. Adjusted Cox hazard models were fitted to predict the risk of community-acquired respiratory infections (acute sinusitis, acute bronchitis, [severe] pneumonia) in patients treated with medical androgen deprivation therapy versus orchiectomy versus none.RESULTS: Overall, 43.4% received medical androgen deprivation therapy. These patients more likely experienced respiratory events compared with those who did not receive androgen deprivation therapy or who underwent orchiectomy (62.2% vs 54.5% vs 47.8%, P < 0.001). The risk of experiencing any respiratory event increased with the number of doses received. For example, men receiving >11 doses of androgen deprivation therapy were at greatest risk of acute sinusitis, acute bronchitis and pneumonia (HR 1.13, 1.26 and 1.15, respectively, all P < 0.001), except severe pneumonia. Furthermore, we did not detect any relationship between orchiectomy and respiratory events. Study limitations include the utilization of a retrospective population-based dataset.CONCLUSIONS: Increased exposure to medical androgen deprivation therapy for men with localized prostate cancer is associated with a higher risk of community-acquired respiratory infections. Our results suggest that respiratory complications represent potentially underreported complications of medical androgen deprivation therapy.
AB - OBJECTIVES: To investigate the dose-dependent effect of androgen deprivation therapy on community-acquired respiratory infections in patients with localized prostate cancer.METHODS: We identified 52 905 men diagnosed with localized prostate cancer within the Surveillance, Epidemiology and End Results-Medicare database between 1991 and 2006. We compared those who did not receive androgen deprivation therapy with those who received androgen deprivation therapy within 2 years of diagnosis, calculated as monthly equivalent doses (<7, 7-11, >11 doses), or orchiectomy. Adjusted Cox hazard models were fitted to predict the risk of community-acquired respiratory infections (acute sinusitis, acute bronchitis, [severe] pneumonia) in patients treated with medical androgen deprivation therapy versus orchiectomy versus none.RESULTS: Overall, 43.4% received medical androgen deprivation therapy. These patients more likely experienced respiratory events compared with those who did not receive androgen deprivation therapy or who underwent orchiectomy (62.2% vs 54.5% vs 47.8%, P < 0.001). The risk of experiencing any respiratory event increased with the number of doses received. For example, men receiving >11 doses of androgen deprivation therapy were at greatest risk of acute sinusitis, acute bronchitis and pneumonia (HR 1.13, 1.26 and 1.15, respectively, all P < 0.001), except severe pneumonia. Furthermore, we did not detect any relationship between orchiectomy and respiratory events. Study limitations include the utilization of a retrospective population-based dataset.CONCLUSIONS: Increased exposure to medical androgen deprivation therapy for men with localized prostate cancer is associated with a higher risk of community-acquired respiratory infections. Our results suggest that respiratory complications represent potentially underreported complications of medical androgen deprivation therapy.
U2 - 10.1111/iju.13043
DO - 10.1111/iju.13043
M3 - SCORING: Journal article
C2 - 26763083
VL - 23
SP - 305
EP - 311
JO - INT J UROL
JF - INT J UROL
SN - 0919-8172
IS - 4
ER -
